Gut microbiota—a future therapeutic target for people with non-alcoholic fatty liver disease: a systematic review
File(s)
Published version
Author(s)
Forlano, Roberta
Sivakumar, Mathuri
Mullish, Benjamin H
Manousou, Pinelopi
Type
Journal Article
Abstract
Non-alcoholic fatty liver disease (NAFLD) represents an increasing cause of liver disease, affecting one-third of the population worldwide. Despite many medications being in the pipeline to treat the condition, there is still no pharmaceutical agent licensed to treat the disease. As intestinal bacteria play a crucial role in the pathogenesis and progression of liver damage in patients with NAFLD, it has been suggested that manipulating the microbiome may represent a therapeutical option. In this review, we summarise the latest evidence supporting the manipulation of the intestinal microbiome as a potential therapy for treating liver disease in patients with NAFLD.
Date Issued
2022-07-27
Date Acceptance
2022-07-25
Citation
International Journal of Molecular Sciences, 2022, 23 (15), pp.1-13
ISSN
1422-0067
Publisher
MDPI AG
Start Page
1
End Page
13
Journal / Book Title
International Journal of Molecular Sciences
Volume
23
Issue
15
Copyright Statement
© 2022 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and
conditions of the Creative Commons
Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Licensee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and
conditions of the Creative Commons
Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
License URL
Identifier
https://www.mdpi.com/1422-0067/23/15/8307
Subjects
Chemical Physics
0399 Other Chemical Sciences
0604 Genetics
0699 Other Biological Sciences
Publication Status
Published
Date Publish Online
2022-07-27